litlas
Log inCreate account

David P. Steensma

Active 2000–2025

123
Papers
19,476
Citations
79
h-index
120
i10-index

Citations

Citations per year for David P. Steensma1996: 1 citations2001: 1 citations2003: 5 citations2004: 15 citations2005: 34 citations2006: 74 citations2007: 87 citations2008: 91 citations2009: 68 citations2010: 95 citations2011: 68 citations2012: 93 citations2013: 98 citations2014: 106 citations2015: 119 citations2016: 166 citations2017: 199 citations2018: 201 citations2019: 675 citations2020: 797 citations2021: 951 citations2022: 799 citations2023: 591 citations2024: 784 citations2025: 379 citations2026: 11 citations1997–2000: no citations, so these years are not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,630 citing papers, 30.7% of this breakdownGermany: 657 citing papers, 7.7% of this breakdownItaly: 583 citing papers, 6.8% of this breakdownUnited Kingdom: 556 citing papers, 6.5% of this breakdownChina: 490 citing papers, 5.7% of this breakdownFrance: 433 citing papers, 5.1% of this breakdownCanada: 306 citing papers, 3.6% of this breakdownSpain: 303 citing papers, 3.5% of this breakdownNetherlands: 228 citing papers, 2.7% of this breakdownAustralia: 212 citing papers, 2.5% of this breakdownJapan: 200 citing papers, 2.3% of this breakdownSwitzerland: 185 citing papers, 2.2% of this breakdown
0%30.7%Other 20.7%

Institutions

Fields

  • Medicine74.8%
  • Biochemistry, Genetics and Molecular Biology16.6%
  • Immunology and Microbiology5.5%
  • Health Professions0.9%
  • Computer Science0.5%
  • Engineering0.3%
  • Other1.4%

Topics

  • Acute Myeloid Leukemia Research15.6%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment9.1%
  • Cancer Genomics and Diagnostics3.2%
  • Hematopoietic Stem Cell Transplantation3.2%
  • Chronic Myeloid Leukemia Treatments2.8%
  • Epigenetics and DNA Methylation2.7%
  • Other63.4%

Coauthors

All papers

Open in search
  1. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

    Authors: David P. Steensma, Rafael Bejar, Siddhartha Jaiswal, R. Coleman Lindsley, Mikkael A. Sekeres, Robert P. Hasserjian, Benjamin L. Ebert - Blood 2015 cited by 1,930

  2. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

    Authors: R. Coleman Lindsley, Brenton G. Mar, Emanuele Mazzola, Peter Grauman, Sarah J. Shareef, Steven L. Allen, Arnaud Pigneux, Meir Wetzler, Robert K. Stuart, Harry P. Erba, Lloyd E. Damon, Bayard L. Powell, Neal I. Lindeman, David P. Steensma, Martha Wadleigh, Daniel J. DeAngelo, Donna Neuberg, Richard M. Stone, Benjamin L. Ebert - Blood 2014 cited by 977

  3. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

    Authors: David A. Sallman, Amy E. DeZern, Guillermo Garcia‐Manero, David P. Steensma, Gail J. Roboz, Mikkael A. Sekeres, Thomas Cluzeau, Kendra Sweet, Amy F. McLemore, Kathy L. McGraw, John Puskas, Ling Zhang, Jiqiang Yao, Qianxing Mo, Lisa Nardelli, Najla H. Al Ali, Eric Padron, Greg Korbel, Eyal C. Attar, Hagop M. Kantarjian, Jeffrey E. Lancet, Pierre Fenaux, Alan F. List, Rami S. Komrokji - Journal of Clinical Oncology 2021 cited by 460

  4. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms

    Authors: Ofir Wolach, Rob S. Sellar, Kimberly Martinod, Deya Cherpokova, Marie McConkey, Ryan Chappell, Alexander J. Silver, Dylan Adams, Cecilia A. Castellano, Rebekka K. Schneider, Robert F. Padera, Daniel J. DeAngelo, Martha Wadleigh, David P. Steensma, Ilene Galinsky, Richard M. Stone, Giulio Genovese, Steven A. McCarroll, Bozenna Iliadou, Christina M. Hultman, Donna Neuberg, Ann Mullally, Denisa D. Wagner, Benjamin L. Ebert - Science Translational Medicine 2018 cited by 454

  5. Bone marrow niches in haematological malignancies

    Authors: Simón Méndez‐Ferrer, Dominique Bonnet, David P. Steensma, Robert P. Hasserjian, Irene M. Ghobrial, John G. Gribben, Michael Andreeff, Daniela S. Krause - Nature reviews. Cancer 2020 cited by 468

  6. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

    Authors: Luca Malcovati, Kristen E. Stevenson, Elli Papaemmanuil, Donna Neuberg, Rafael Bejar, Jacqueline Boultwood, David Bowen, Peter J. Campbell, Benjamin L. Ebert, Pierre Fenaux, Torsten Haferlach, Michael Heuser, Joop H. Jansen, Rami S. Komrokji, Jaroslaw P. Maciejewski, Matthew J. Walter, Michaëla Fontenay, Guillermo Garcia‐Manero, Timothy A. Graubert, Aly Karsan, Manja Meggendorfer, Andrea Pellagatti, David A. Sallman, Michael R. Savona, Mikkael A. Sekeres, David P. Steensma, Sudhir Tauro, Felicitas Thol, Paresh Vyas, Arjan A. van de Loosdrecht, Detlef Haase, Heinz Tüchler, Peter L. Greenberg, Seishi Ogawa, Eva Hellström‐Lindberg, Mario Cazzola - Blood 2020 cited by 293

  7. Clonal Hematopoiesis

    Authors: Peter Libby, Robert Sidlow, Amy E. Lin, Dipti Gupta, Lee W. Jones, Javid J. Moslehi, Andreas M. Zeiher, Siddhartha Jaiswal, Christian Schulz, Ron Blankstein, Kelly L. Bolton, David P. Steensma, Ross L. Levine, Benjamin L. Ebert - Journal of the American College of Cardiology 2019 cited by 237

  8. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

    Authors: David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji, Jay Yang, Andrew M. Brunner, Hetty E. Carraway, Lionel Adès, Aref Al‐Kali, Juan Manuel Alonso‐Domínguez, Ana Alfonso Piérola, Catherine C. Coombs, H. Joachim Deeg, Ian W. Flinn, James M. Foran, Guillermo Garcia‐Manero, Michael B. Maris, Malgorzata McMasters, Jean‐Baptiste Micol, Jaime Pérez de Oteyza, Felicitas Thol, Eunice S. Wang, Justin M. Watts, Justin Taylor, Richard M. Stone, Vikram Gourineni, Alyssa J. Marino, Huilan Yao, Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker - Leukemia 2021 cited by 178

  9. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

    Authors: Guillermo Garcia‐Manero, Elizabeth A. Griffiths, David P. Steensma, Gail J. Roboz, Richard A. Wells, James McCloskey, Olatoyosi Odenike, Amy E. DeZern, Karen Yee, Lambert Busque, Casey L. O’Connell, Laura C. Michaelis, Joseph Brandwein, Hagop M. Kantarjian, Aram Oganesian, Mohammad Azab, Michael R. Savona - Blood 2020 cited by 210

  10. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant

    Authors: Tarek H. Mouhieddine, Adam S. Sperling, Robert Redd, Jihye Park, Matthew Leventhal, Christopher J. Gibson, Salomon Manier, Amin H. Nassar, Marzia Capelletti, Daisy Huynh, Mark Bustoros, Romanos Sklavenitis‐Pistofidis, Sabrin Tahri, Kalvis Hornburg, Henry Dumke, Muhieddine M. Itani, Cody J. Boehner, Chia‐Jen Liu, Saud H. AlDubayan, Brendan Reardon, Eliezer M. Van Allen, Jonathan J. Keats, Chip Stewart, Shaadi Mehr, Daniel Auclair, Robert Schlossman, Nikhil C. Munshi, Kenneth C. Anderson, David P. Steensma, Jacob P. Laubach, Paul G. Richardson, Jerome Ritz, Benjamin L. Ebert, Robert J. Soiffer, Lorenzo Trippa, Gad Getz, Donna Neuberg, Irene M. Ghobrial - Nature Communications 2020 cited by 166

  11. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

    Authors: Detlef Haase, Kristen E. Stevenson, Donna Neuberg, Jaroslaw P. Maciejewski, Aziz Nazha, Mikkael A. Sekeres, Benjamin L. Ebert, Guillermo Garcia‐Manero, Claudia Haferlach, Torsten Haferlach, Wolfgang Kern, Seishi Ogawa, Yasunobu Nagata, Kenichi Yoshida, Timothy A. Graubert, Matthew J. Walter, Alan F. List, Rami S. Komrokji, Eric Padron, David A. Sallman, Elli Papaemmanuil, Peter J. Campbell, Michael R. Savona, Adam C. Seegmiller, Lionel Adès, Pierre Fenaux, Lee‐Yung Shih, David Bowen, Michael J. Groves, Sudhir Tauro, Michaëla Fontenay, Olivier Kosmider, Michal Bar‐Natan, David P. Steensma, Richard M. Stone, Michael Heuser, Felicitas Thol, Mario Cazzola, Luca Malcovati, Aly Karsan, Christina Ganster, Eva Hellström‐Lindberg, Jacqueline Boultwood, Andrea Pellagatti, Valeria Santini, Lynn Quek, Paresh Vyas, Heinz Tüchler, Peter L. Greenberg, Rafael Bejar - Leukemia 2019 cited by 259

  12. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes

    Authors: Aziz Nazha, Rami Komrokji, Manja Meggendorfer, Xuefei Jia, Nathan Radakovich, Jacob Shreve, C. Beau Hilton, Yasunubo Nagata, Betty K. Hamilton, Sudipto Mukherjee, Najla Al Ali, Wencke Walter, Stephan Hutter, Eric Padron, David Sallman, Teodora Kuzmanovic, Cassandra Kerr, Vera Adema, David P. Steensma, Amy Dezern, Gail Roboz, Guillermo Garcia-Manero, Harry Erba, Claudia Haferlach, Jaroslaw P. Maciejewski, Torsten Haferlach, Mikkael A. Sekeres - Journal of Clinical Oncology 2021 cited by 166

  13. Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia

    Authors: Robert P. Hasserjian, David P. Steensma, Timothy A. Graubert, Benjamin L. Ebert - Blood 2020 cited by 123

  14. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

    Authors: Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steven Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia‐Manero, Norbert Vey, Martin Wermke, Jeroen J. W. M. Janssen, Rupa Narayan, Shaun Fleming, Sun Loo, Natalia Tovar, Mika Kontro, Oliver G. Ottmann, Purushotham Naidu, Haiying Sun, May Han, Roisin White, Na Zhang, Anisa Mohammed, Catherine Sabatos-Peyton, David P. Steensma, Mikael L. Rinne, Uma Borate, Andrew H. Wei - American Journal of Hematology 2023 cited by 46

  15. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

    Authors: Rafael Bejar, Allegra M. Lord, Kristen E. Stevenson, Michal Bar‐Natan, Albert Pérez-Ladaga, Jacques Zaneveld, Hui Wang, Bennett Adam Caughey, Petar Stojanov, Gad Getz, Guillermo Garcia‐Manero, Hagop M. Kantarjian, Rui Chen, Richard M. Stone, Donna Neuberg, David P. Steensma, Benjamin L. Ebert - Blood 2014 cited by 556

  16. Clinical consequences of clonal hematopoiesis of indeterminate potential

    Authors: David P. Steensma - Blood Advances 2018 cited by 193

  17. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

    Authors: Uwe Platzbecker, Pierre Fenaux, Lionel Adès, Aristoteles Giagounidis, Valeria Santini, Arjan A. van de Loosdrecht, David Bowen, T. de Witte, Guillermo Garcia‐Manero, Eva Hellström‐Lindberg, Ulrich Germing, Reinhard Stauder, Luca Malcovati, Mikkael A. Sekeres, David P. Steensma, Silke Gloaguen - Blood 2018 cited by 178

  18. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

    Authors: Animesh Pardanani, Ross L. Levine, Terra L. Lasho, Yana Pikman, Ruben A. Mesa, Martha Wadleigh, David P. Steensma, Michelle A. Elliott, Alexandra P. Wolanskyj, William J. Hogan, Rebecca F. McClure, Mark R. Litzow, D. Gary Gilliland, Ayalew Tefferi - Blood 2006 cited by 1,039

  19. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

    Authors: Shuo-Chieh Wu, Loretta S. Li, Nadja Kopp, Joan Montero, Bjoern Chapuy, Akinori Yoda, Amanda L. Christie, Huiyun Liu, Alexandra Christodoulou, Diederik van Bodegom, Jordy Van Der Zwet, Jacob V. Layer, Trevor Tivey, Andrew A. Lane, Jeremy Ryan, Samuel Y. Ng, Daniel J. DeAngelo, Richard M. Stone, David P. Steensma, Martha Wadleigh, Marian H. Harris, Emeline Mandon, Nicolas Ebel, Rita Andraos, Vincent Romanet, Arno Dölemeyer, Dario Sterker, Michael Zender, Scott J. Rodig, Masato Murakami, Francesco Hofmann, Frank C. Kuo, Michael J. Eck, Lewis B. Silverman, Stephen E. Sallan, Anthony Letai, Fabienne Baffert, Eric Vangrevelinghe, Thomas Radimerski, Christoph Gaul, David M. Weinstock - Cancer Cell 2015 cited by 123

  20. Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial

    Authors: Janghee Woo, Darlene Lu, Andrew Lewandowski, Huilei Xu, Pablo Serrano Balazote, Margaret L. Healey, Denise P. Yates, Michael T. Beste, Peter Libby, Paul M. Ridker, David P. Steensma - Blood Advances 2023 cited by 45

  21. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

    Authors: Jacalyn Rosenblatt, Richard M. Stone, Lynne Uhl, Donna Neuberg, Robin Joyce, James D. Levine, Jon Arnason, Malgorzata McMasters, Katarina Luptakova, Salvia Jain, Jeffrey I. Zwicker, Ayad Hamdan, Vassiliki A. Boussiotis, David P. Steensma, Daniel J. DeAngelo, Ilene Galinsky, Poorvi Somaiya Dutt, Emma Logan, Mary Paty Bryant, Dina Stroopinsky, Lillian Werner, Kristen Palmer, Max Coll, Abigail Washington, Leandra Cole, Donald Küfe, David Avigan - Science Translational Medicine 2016 cited by 164

  22. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

    Authors: David P. Steensma, Pierre Fenaux, Koen Van Eygen, Azra Raza, Valeria Santini, Ulrich Germing, Patricia Font, María Díez‐Campelo, Sylvain Thépot, Edo Vellenga, Mrinal M. Patnaik, Jun Ho Jang, Helen Varsos, Jacqueline Bussolari, Esther Rose, Laurie Sherman, Libo Sun, Ying Wan, Souria Dougherty, Fei Huang, Faye Feller, Aleksandra Rizo, Uwe Platzbecker - Journal of Clinical Oncology 2020 cited by 125

  23. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

    Authors: Elizabeth C. Townsend, Mark A. Murakami, Alexandra Christodoulou, Amanda L. Christie, Johannes Köster, Tiffany DeSouza, Elizabeth A. Morgan, Scott P. Kallgren, Huiyun Liu, Shuo-Chieh Wu, Olivia D. Plana, Joan Montero, Kristen E. Stevenson, Prakash K. Rao, Raga Vadhi, Michael Andreeff, Philippe Armand, Karen K. Ballen, Patrizia Barzaghi-Rinaudo, Sarah Cahill, Rachael A. Clark, Vesselina G. Cooke, Matthew S. Davids, Daniel J. DeAngelo, David M. Dorfman, Hilary Eaton, Benjamin L. Ebert, Julia Etchin, Brant Firestone, David C. Fisher, Arnold S. Freedman, Ilene Galinsky, Hui Gao, Jacqueline S. Garcia, Francine Garnache‐Ottou, Timothy A. Graubert, Alejandro Gutiérrez, Ensar Halilovic, Marian H. Harris, Zachary T. Herbert, Steven M. Horwitz, Giorgio Inghirami, Andrew M. Intlekofer, Moriko Ito, Shai Izraeli, Eric D. Jacobsen, Caron A. Jacobson, Sébastien Jeay, Irmela Jeremias, Michelle A. Kelliher, Raphael Koch, Marina Konopleva, Nadja Kopp, Steven M. Kornblau, Andrew L. Kung, Thomas S. Kupper, Nicole R. LeBoeuf, Ann S. LaCasce, Emma Lees, Loretta S. Li, A. Thomas Look, Masato Murakami, Markus Müschen, Donna Neuberg, Samuel Y. Ng, Oreofe O. Odejide, Stuart H. Orkin, Rachel R. Paquette, Andrew E. Place, Justine E. Roderick, Jeremy Ryan, Stephen E. Sallan, Brent Shoji, Lewis B. Silverman, Robert J. Soiffer, David P. Steensma, Kimberly Stegmaier, Richard M. Stone, Jérôme Tamburini, Aaron R. Thorner, Paul Van Hummelen, Martha Wadleigh, Marion Wiesmann, Andrew P. Weng, Jens Wuerthner, David A. Williams, Bruce M. Wollison, Andrew A. Lane, Anthony Letai, Monica M. Bertagnolli, Jerome Ritz, Myles Brown, Henry W. Long, Jon C. Aster, Margaret A. Shipp, James D. Griffin, David M. Weinstock - Cancer Cell 2016 cited by 304

  24. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

    Authors: Michael R. Savona, Olatoyosi Odenike, Philip C. Amrein, David P. Steensma, Amy E. DeZern, Laura C. Michaelis, Stefan Faderl, Wael A. Harb, Hagop M. Kantarjian, James N. Lowder, Aram Oganesian, Mohammad Azab, Guillermo Garcia‐Manero - The Lancet Haematology 2019 cited by 120